Cargando…
Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer
BACKGROUND: Improved methods are needed for predicting prognosis and the benefit of delivering adjuvant chemotherapy (ACT) in patients with non-small-cell lung cancer (NSCLC). METHODS: A novel prognostic algorithm was identified using genomic profiles from 332 stage I-III adenocarcinomas and indepen...
Autor principal: | Van Laar, Ryan K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407714/ https://www.ncbi.nlm.nih.gov/pubmed/22748043 http://dx.doi.org/10.1186/1755-8794-5-30 |
Ejemplares similares
-
Is there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer?
por: Liu, Yutao, et al.
Publicado: (2017) -
Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2018) -
A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer
por: Wang, Xiangxue, et al.
Publicado: (2021) -
A MicroRNA Signature Predicts Survival in Early Stage Small-Cell Lung Cancer Treated with Surgery and Adjuvant Chemotherapy
por: Bi, Nan, et al.
Publicado: (2014) -
Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid Tumors
por: Sobash, Philip T., et al.
Publicado: (2022)